Literature DB >> 10094303

The role of overlapping U1 and U11 5' splice site sequences in a negative regulator of splicing.

C S Hibbert1, R R Gontarek, K L Beemon.   

Abstract

Splicing of Rous sarcoma virus RNA is regulated in part by a cis-acting intronic RNA element called the negative regulator of splicing (NRS). An NRS mutant affecting nt 916-923 disrupts U11 snRNP binding and reduces NRS activity (Gontarek et al., 1993, Genes & Dev 7:1926-1936). However, we observed that a U15' splice site-like sequence, which overlapped the U11 site, was also disrupted by this mutation. To determine whether the U1 or the U11 site was essential for NRS activity, we analyzed twelve additional mutants involving nt 915-926. All mutations that disrupted the potential base pairing between U1 snRNA and the NRS reduced NRS activity, including single point mutations at nt 915, 916, and 919. The point mutation at nt 919 was partially suppressed by a compensatory base change mutation in U1 snRNA. In contrast, a mutation which strengthened the potential base pairing between the U1 site and the NRS increased NRS activity. Surprisingly, mutations that specifically targeted the U115' splice site consensus sequence increased the levels of unspliced RNA, suggesting U11 binding plays an antagonistic role to NRS activity. We propose that U1 snRNP binding to the NRS inhibits splicing and is regulated by U11 snRNP binding to the overlapping sequence. Competition between U1 and U11 snRNPs would result in the appropriate balance of spliced to unspliced RNAs for optimal viral replication. Further, a virus mutated in the U1/U11 region of the NRS was found to have delayed replication.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10094303      PMCID: PMC1369763          DOI: 10.1017/s1355838299981347

Source DB:  PubMed          Journal:  RNA        ISSN: 1355-8382            Impact factor:   4.942


  45 in total

1.  U1 small nuclear RNA plays a direct role in the formation of a rev-regulated human immunodeficiency virus env mRNA that remains unspliced.

Authors:  X B Lu; J Heimer; D Rekosh; M L Hammarskjöld
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

2.  Nonsense codons within the Rous sarcoma virus gag gene decrease the stability of unspliced viral RNA.

Authors:  G F Barker; K Beemon
Journal:  Mol Cell Biol       Date:  1991-05       Impact factor: 4.272

3.  Control of retroviral RNA splicing through maintenance of suboptimal processing signals.

Authors:  R A Katz; A M Skalka
Journal:  Mol Cell Biol       Date:  1990-02       Impact factor: 4.272

4.  Multiple regions in the Rous sarcoma virus src gene intron act in cis to affect the accumulation of unspliced RNA.

Authors:  C M Stoltzfus; S J Fogarty
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

5.  cis-acting regulatory elements within gag genes of avian retroviruses.

Authors:  S Arrigo; M Yun; K Beemon
Journal:  Mol Cell Biol       Date:  1987-01       Impact factor: 4.272

6.  A compensatory base change in U1 snRNA suppresses a 5' splice site mutation.

Authors:  Y Zhuang; A M Weiner
Journal:  Cell       Date:  1986-09-12       Impact factor: 41.582

7.  cis-acting intron mutations that affect the efficiency of avian retroviral RNA splicing: implication for mechanisms of control.

Authors:  R A Katz; M Kotler; A M Skalka
Journal:  J Virol       Date:  1988-08       Impact factor: 5.103

Review 8.  Synthesis and processing of avian sarcoma retrovirus RNA.

Authors:  C M Stoltzfus
Journal:  Adv Virus Res       Date:  1988       Impact factor: 9.937

9.  Nucleotide sequence of Rous sarcoma virus.

Authors:  D E Schwartz; R Tizard; W Gilbert
Journal:  Cell       Date:  1983-03       Impact factor: 41.582

10.  Regulation of Rous sarcoma virus RNA splicing and stability.

Authors:  S Arrigo; K Beemon
Journal:  Mol Cell Biol       Date:  1988-11       Impact factor: 4.272

View more
  22 in total

1.  Identification of a bidirectional splicing enhancer: differential involvement of SR proteins in 5' or 3' splice site activation.

Authors:  C F Bourgeois; M Popielarz; G Hildwein; J Stevenin
Journal:  Mol Cell Biol       Date:  1999-11       Impact factor: 4.272

2.  Retroviral splicing suppressor requires three nonconsensus uridines in a 5' splice site-like sequence.

Authors:  R E Paca; C S Hibbert; C T O'Sullivan; K L Beemon
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  SRp30c is a repressor of 3' splice site utilization.

Authors:  Martin J Simard; Benoit Chabot
Journal:  Mol Cell Biol       Date:  2002-06       Impact factor: 4.272

4.  Solution structure of the pseudo-5' splice site of a retroviral splicing suppressor.

Authors:  Javier Cabello-Villegas; Keith E Giles; Ana Maria Soto; Ping Yu; Annie Mougin; Karen L Beemon; Yun-Xing Wang
Journal:  RNA       Date:  2004-09       Impact factor: 4.942

5.  Retroviral splicing suppressor sequesters a 3' splice site in a 50S aberrant splicing complex.

Authors:  Keith E Giles; Karen L Beemon
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

6.  The negative regulator of splicing element of Rous sarcoma virus promotes polyadenylation.

Authors:  Jeremy E Wilusz; Karen L Beemon
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

7.  Serine/arginine-rich proteins contribute to negative regulator of splicing element-stimulated polyadenylation in rous sarcoma virus.

Authors:  Nicole L Maciolek; Mark T McNally
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

8.  Efficient polyadenylation of Rous sarcoma virus RNA requires the negative regulator of splicing element.

Authors:  Brent L Fogel; Lisa M McNally; Mark T McNally
Journal:  Nucleic Acids Res       Date:  2002-02-01       Impact factor: 16.971

Review 9.  RNA processing control in avian retroviruses.

Authors:  Mark T McNally
Journal:  Front Biosci       Date:  2008-05-01

10.  Silent point mutation in an avian retrovirus RNA processing element promotes c-myb-associated short-latency lymphomas.

Authors:  Tatjana S Polony; Sandra J Bowers; Paul E Neiman; Karen L Beemon
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.